Isomorphic Labs will accelerate its AI-led drug discovery efforts following a $5 billion Series C funding round co-led by Greenoaks and Sequoia Capital. The financing will support the company’s work to refine its IsoDDE drug design engine, expand its therapeutic candidate pipeline, and build a global AI-led bioengineering infrastructure. “Our drug design engine is generating molecules with precision and speed,” said Sir Demis Hassabis, Founder and CEO of Isomorphic Labs, adding that the round enables the company to drive its first therapeutic programs towards clinical trials.
$5 Billion Series C Co-Led by Greenoaks and Sequoia Capital
The financing will support the company’s efforts to build scalable AI-first translational and clinical development infrastructure, accelerating the progression of its drug candidates toward clinical trials. This investment signals a significant commitment to AI-led bioengineering and the potential for accelerating drug discovery processes. The infusion of capital will also be directed toward maturing Isomorphic’s proprietary drug design engine, IsoDDE, and deepening its exploration of complex biological systems with advanced models.
According to Neil Mehta, Founder and Managing Partner of Greenoaks, “Discovering and developing new medicines is an optimization challenge of almost infinite scale,” and Isomorphic is uniquely positioned to transform this process through its deep learning systems. The company’s approach focuses on predicting biological behaviors with accuracy and systematically mapping the path to new medicines, a strategy that has attracted substantial investor confidence.
Max Jaderberg, President of Isomorphic Labs, emphasized the consistent scientific advancements being made, stating, “Every week we are making repeatable scientific advancements enabled by our models.” These advancements are directly translating into improved molecular profiles with the potential to address some of the most challenging problems in drug discovery, a process traditionally hampered by complex biological hurdles. Isomorphic’s interdisciplinary teams, combining machine learning expertise with seasoned drug hunters, are solving these long-standing problems and translating discoveries into potential life-changing medicines.
The company’s pipeline includes both internal programs in oncology and immunology, as well as partnered programs, all of which are showing positive preclinical results. This momentum is setting the stage for clinical entry, indicating a rapid translation of AI-driven insights into tangible therapeutic candidates.
Isomorphic is also actively building a partner ecosystem to further enhance the understanding of mechanistic disease biology, recognizing that collaboration is essential for accelerating innovation. Konstantine Buhler, Partner at Sequoia Capital, highlighted the transformative potential of Isomorphic’s technology, stating, “Isomorphic Labs is building foundational technology for the future of medicine.” He further noted that the company’s ability to translate advanced AI into a growing portfolio of drug candidates is particularly inspiring, demonstrating the importance of applying AI to improve human health.
Founded in 2021, Isomorphic Labs was built on the conviction that biology can be understood and modeled at a fundamental molecular level through the application of artificial intelligence. The company’s headquarters are in London, with additional office locations in Cambridge, Massachusetts and Lausanne, Switzerland, reflecting its commitment to establishing a global presence in key innovation hubs. Isomorphic Labs is currently advancing a broad and ambitious drug design portfolio through both partnered programs and wholly-owned internal programs, signaling a many-sided approach to tackling complex medical challenges.
Isomorphic Labs is building foundational technology for the future of medicine.
Konstantine Buhler, Partner at Sequoia Capital




See today’s quantum computing news on Quantum Zeitgeist for the latest breakthroughs in qubits, hardware, algorithms, and industry deals.
